Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CombinatoRx has been granted a US patent covering combinations of tricyclic antidepressants or TCA and glucocorticosteroids for the treatment of inflammatory disorders.
Subscribe to our email newsletter
This patent contains claims covering CRx-191, the company’s lead topical dermatology product candidate, and other product candidates, and will expire in 2022, unless extended.
Alexis Borisy, president and CEO of CombinatoRx, said: “This is a significant addition to our growing intellectual property estate, and we anticipate the issuance of additional patents covering CombinatoRx product candidates in the near future.”